Considering the large number of 2OG-dependent oxygenases, and their broad functional roles in various fundamental biological processes, we considered it important to develop a highly selective PHD inhibitor suitable for use in AML therapy. The gene discussed is PDC; the disease is acute myeloid leukemia.